Price
No data yet.
Social Signal Score
Revenue
$179.0K-87.21%Company Profile
- CEO
- Howard S. Jonas
- Sector
- Real Estate
- Industry
- Real Estate - Services
- Employees
- 22
- Beta
- 0.35
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.41
Financials
Revenue
$179.0K-87.2%Net Income
$-4.23M-3508.1%EBITDA
$-2.84M-637.5%Free Cash Flow
$-7.28MEPS (diluted)
$-0.08-933.3%Shares Outstanding (diluted)
51.23M+308.5%Operating Expenses
$6.99MCash & Debt
$30.50MReturn of Capital
$0.00Revenue by Segment (annual)
$279.0KDividend per Share
$0.02Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $917.0K | $-30.52M | $-1.04 |
| 2024 | $637.0K | $-34.41M | $-1.45 |
| 2023 | $279.0K | $-1.88M | $-0.08 |
| 2022 | $410.0K | $-124.66M | $-6.31 |
| 2021 | $802.0K | $-24.54M | $-1.47 |
| 2020 | $4.91M | $-10.41M | $-0.44 |
| 2019 | $4.93M | $-4.92M | $-0.37 |
| 2018 | $4.37M | $-11.65M | $-0.93 |
| 2017 | $5.62M | $138.0K | $0.01 |
| 2016 | $5.59M | $710.0K | $0.06 |
| 2015 | $3.99M | $-467.0K | $-0.04 |
Valuation
RFLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
23-85.42%Social Signal Score
Mentions (3)
- Newsmarketbeat.com·2d ago·Negative
Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing Rafael NYSE: RFL reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC) Trappsol ® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% o
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Estimates and results for RFL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RFL officers and directors.
- Bought
- $16.7m
- Sold
- —
3 trades
0 trades
- Jonas Howard Sboughtdirector, 10 percent owner, officer: Exec Chairman, CEO & President·12,299,207 @ $1.28·$15.7m·Jun 5, 2025·filing
- Jonas Howard Sboughtdirector, 10 percent owner, officer: Exec Chairman, CEO & President·457,031 @ $1.28·$585k·Jun 5, 2025·filing
- Jonas Howard Sboughtdirector, 10 percent owner, officer: Exec Chairman, CEO & President·324,219 @ $1.28·$415k·Jun 5, 2025·filing
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RFL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.